Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiving erythropoiesis-stimulating agents.
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Paricalcitol (Primary)
- Indications Anaemia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms PIERIAD STUDY
- 02 Apr 2018 New trial record